Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application

摘要: Cancer is the leading cause of disease worldwide, characterized by uncontrolled cell proliferation, evasion apoptosis, inflammation, cellular differentiation, survival, invasion, and angiogenesis. Conventional chemotherapy, which standard treatment for most advanced cancers, kills normal malignant cells in an indiscriminate manner. However, nanotechnological drug carriers can be considered as ideal candidates cancer since they make use abnormal characteristics tumor tissues and, either through active, passive, or specific targeting, selectively destroy cells, avoiding healthy ones. Additionally, nanomedicine products improve properties traditional anticancer drugs, enhancing efficacy therapeutic index these compounds. Moreover, adequate nanoplatforms also efficient theranostic approaches, enabling a simultaneous diagnosis at tissue. Some nanocarriers incorporating cytotoxic agents, such liposomes, polymeric nanoparticles, micelles, polymer- lipid–drug conjugate have already been developed are currently market, while others still under clinical preclinical research. In this chapter, we highlight latest innovations nanotherapeutics, including detailed description different nanotechnology-based drug-delivery systems used therapy, those development, well important studies up to date. Therefore, novel nanocarrier approaches might open new alternatives intervention cancer.